3,046 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division acquired a new position in shares of Zoetis Inc. (NYSE:ZTSFree Report) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 3,046 shares of the company’s stock, valued at approximately $509,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Blue Bell Private Wealth Management LLC lifted its holdings in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares in the last quarter. Webster Bank N. A. lifted its holdings in Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after buying an additional 82 shares in the last quarter. Independence Bank of Kentucky lifted its holdings in Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after buying an additional 130 shares in the last quarter. Private Wealth Management Group LLC acquired a new stake in Zoetis during the 4th quarter worth approximately $33,000. Finally, Ramirez Asset Management Inc. acquired a new stake in Zoetis during the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Performance

ZTS traded down $1.77 on Wednesday, reaching $172.47. The company had a trading volume of 140,701 shares, compared to its average volume of 2,893,247. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The stock has a market capitalization of $78.70 billion, a PE ratio of 33.57, a P/E/G ratio of 2.72 and a beta of 0.86. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. The stock has a 50-day moving average price of $171.62 and a 200-day moving average price of $177.52.

Zoetis (NYSE:ZTSGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.31 earnings per share. As a group, research analysts forecast that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.00%. Zoetis’s dividend payout ratio is presently 33.33%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Barclays decreased their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. The Goldman Sachs Group decreased their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Finally, HSBC decreased their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $211.75.

View Our Latest Report on Zoetis

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Further Reading

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.